File Download
Patent History
- ApplicationUS 12/502548 2009-07-14
- PublicationUS 2010008925 2010-01-14
Patent Family
Supplementary
-
Citations:
- Appears in Collections:
published patent: METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTOXIN-MEDIATED PRO-INFLAMMATORY RESPONSES
Title | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTOXIN-MEDIATED PRO-INFLAMMATORY RESPONSES |
---|---|
Priority Date | 2009-07-14 US 12/502548 2008-07-14 US 12/080558P |
Inventors | |
Issue Date | 2010 |
Citation | US Published patent application US 2010008925. Washington, DC: US Patent and Trademark Office (USPTO), 2010 How to Cite? |
Abstract | Bacterial lipopolysaccharide (LPS) in systemic circulation triggers deleterious super-inflammatory response, which is key pathogenesis of many disorders like gram-negative sepsis and necrotizing enterocolitis. No effective therapeutic interventions are currently available for protection of patients against mortality. Disclosed are methods and therapeutic agents that ablate the biological toxicity of LPS in circulation (Integrin Peptide), and abrogate leukocyte infiltration into lung and liver and suppress adhesion molecule expression (Integrin Peptide and Anti-CD18 betaA scFv). These therapeutic agents can be used alone, or in combination for treatment of endotoxin-mediated pro-inflammatory responses, particularly in cases of acute sepsis and necrotizing enterocolitis. |
Persistent Identifier | http://hdl.handle.net/10722/176988 |
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2012-11-30T08:38:54Z | - |
dc.date.available | 2012-11-30T08:38:54Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | US Published patent application US 2010008925. Washington, DC: US Patent and Trademark Office (USPTO), 2010 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/176988 | - |
dc.description.abstract | Bacterial lipopolysaccharide (LPS) in systemic circulation triggers deleterious super-inflammatory response, which is key pathogenesis of many disorders like gram-negative sepsis and necrotizing enterocolitis. No effective therapeutic interventions are currently available for protection of patients against mortality. Disclosed are methods and therapeutic agents that ablate the biological toxicity of LPS in circulation (Integrin Peptide), and abrogate leukocyte infiltration into lung and liver and suppress adhesion molecule expression (Integrin Peptide and Anti-CD18 betaA scFv). These therapeutic agents can be used alone, or in combination for treatment of endotoxin-mediated pro-inflammatory responses, particularly in cases of acute sepsis and necrotizing enterocolitis. | en_HK |
dc.title | METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTOXIN-MEDIATED PRO-INFLAMMATORY RESPONSES | en_HK |
dc.type | Patent | en_US |
dc.description.nature | published_or_final_version | en_US |
dc.identifier.hkuros | 147154 | - |
dc.contributor.inventor | Luk, JMC | en_HK |
dc.contributor.inventor | Wong Kwong Fai | en_HK |
dc.contributor.inventor | Poon, RTP | en_HK |
dc.contributor.inventor | Fan, ST | en_HK |
patents.identifier.application | US 12/502548 | en_HK |
patents.description.assignee | THE UNIVERSITY OF HONG KONG | en_HK |
patents.description.country | United States of America | en_HK |
patents.date.publication | 2010-01-14 | en_HK |
patents.date.application | 2009-07-14 | en_HK |
patents.date.priority | 2009-07-14 US 12/502548 | en_HK |
patents.date.priority | 2008-07-14 US 12/080558P | en_HK |
patents.description.cc | US | en_HK |
patents.identifier.publication | US 2010008925 | en_HK |
patents.relation.family | CN 102239179 (A) 2011-11-09 | en_HK |
patents.relation.family | US 2010008925 (A1) 2010-01-14 | en_HK |
patents.relation.family | US 7960338 (B2) 2011-06-14 | en_HK |
patents.relation.family | WO 2010006508 (A1) 2010-01-21 | en_HK |
patents.description.kind | A1 | en_HK |
patents.type | Patent_published | en_HK |